A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Key Points

• This analysis aims to compare the efficacy of lenvatinib, atezolizumab plus bevacizumab, and sorafenib in treating unresectable hepatocellular carcinoma.
• Conducted a network meta-analysis of available studies
• Assessed overall survival as the primary outcome
• Calculated hazard ratios (HRs) for treatment comparisons
• Utilized SUCRA rankings to evaluate clinical trends
• Overall survival rates were similar across all treatments
• Hazard ratios showed no statistically significant differences
• SUCRA rankings indicated a trend favoring atezolizumab plus bevacizumab

Abstract